Scott A. Holmes
Plus aucun poste en cours
Profil
Scott A.
Holmes held several finance and administration positions in the biopharmaceutical industry, including Executive Director-Finance & Administration at Molecular Biometrics, Senior Auditor at Ernst & Young LLP, CFO, Chief Accounting Officer & Senior VP at Keryx Biopharmaceuticals, Treasurer, CAO, SVP-Finance & Investor Relations at AMAG Pharmaceuticals, and Vice President-Finance at On-Q-ity, Inc. He also served as Controller at Keryx Biopharmaceuticals and Vice President-Finance & Administration at Dynogen Pharmaceuticals, Inc. Holmes earned an undergraduate degree from Middlebury College and a graduate degree, including an MBA, from Northeastern University.
Anciens postes connus de Scott A. Holmes
| Sociétés | Poste | Fin |
|---|---|---|
| KIADIS PHARMA N.V. | Director of Finance/CFO | 31/12/2019 |
| KERYX BIOPHARMACEUTICALS | Director of Finance/CFO | 12/12/2018 |
| AMAG PHARMACEUTICALS, INC. | Director of Finance/CFO | 23/07/2015 |
Molecular Biometrics, Inc.
 Molecular Biometrics, Inc. Miscellaneous Commercial ServicesCommercial Services Molecular Biometrics, Inc. used to develop analytical methodologies for molecular diagnostic. It developed highly specific and sensitive analytical methodologies for molecular diagnostic and monitoring applications in medicine, and for drug discovery and development through pharmacodiagnostics. The company was founded in 2005 and was headquartered in Norwood, MA. | Corporate Officer/Principal | 01/01/2011 |
On-Q-ity, Inc.
 On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | Director of Finance/CFO | 01/01/2010 |
Formation de Scott A. Holmes
| Middlebury College | Undergraduate Degree |
| Northeastern University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Dynogen Pharmaceuticals, Inc.
 Dynogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dynogen Pharmaceuticals, Inc. develops and manufactures drugs. The company makes drugs for genitourinary and gastrointestinal disorders. It also makes drugs for constipation, Irritable Bowel Syndrome and overactive bladder. Dynogen Pharmaceuticals was founded by Lee R. Brettman in 2002 and is located in Waltham, MA. | Health Technology |
On-Q-ity, Inc.
On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | Health Services |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Molecular Biometrics, Inc.
Molecular Biometrics, Inc. Miscellaneous Commercial ServicesCommercial Services Molecular Biometrics, Inc. used to develop analytical methodologies for molecular diagnostic. It developed highly specific and sensitive analytical methodologies for molecular diagnostic and monitoring applications in medicine, and for drug discovery and development through pharmacodiagnostics. The company was founded in 2005 and was headquartered in Norwood, MA. | Commercial Services |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
